Nachrichten zur Ionis Pharmaceuticals Inc. Aktie

Wall Street Analysts See a 73.42% Upside in Kiniksa Pharmaceuticals (KNSA): Can the Stock Really Move This High?

The consensus price target hints at a 73.4% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this…

…

While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the…

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 41.07% and 65.19%, respectively, for the quarter ended December 2024. Do…

Ionis Pharmaceuticals beats Q4 estimates, guides 2025 revenue below consensus…

Evaluate the expected performance of Ionis Pharmaceuticals (IONS) for the quarter ended December 2024, looking beyond the conventional Wall Street…

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…

…

The mean of analysts price targets for Ionis Pharmaceuticals (IONS) points to a 55.9% upside in the stock. While this…

…

…

Kiniksa Pharmaceuticals (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that…

…

…

…

…

…

…

– Initiative aimed at improving access and outcomes for patients with recurrent pericarditis –…

…

…

Ionis Pharmaceuticals shares get boost by Oppenheimer, cites strong 2024…

Kyle Jenne returns to Ionis Pharmaceuticals as Executive VP…